animal health

/Tag:animal health
­

Bionaturis Group, at the KC Animal Health Investment Forum

The Global Sales Manager at Bionaturis Group, Eli Kehrli, is attending today the commemorative event of the 10th Anniversary of the Kansas City-centered Animal Health Corridor.

The Kansas City-centered Animal Health Corridor is the biggest business and research center devoted to animal health in the world. More than 300 companies are located in this area, considered the “Sillicon Valley” in this sector. With our attendance to this relevant event, in which more than 1,000 experts in the sector are taking part, Bionaturis continues working and strengthening its international strategy.

Bionaturis Group has already presence in USA with the subsidiary of BBD BioPhenix in Maryland and the strategic agreement with Biological Mimetics (BMI) to jointly develop new vaccines for human and animal health applications.

About Bionaturis Group

The Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in the vaccines research, Bionaturis Group closed last exercise with an increase of sales of 73% and a positive EBITDA of 29% compared to the previous year. The biotechnological Group which envisages a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

For further information about the event

September 1st, 2015|Blog english, congress|Comments Off on Bionaturis Group, at the KC Animal Health Investment Forum

Bionaturis summits a new patent application

The new patent intends to protect a new antimicrobial peptide, Garvicin A, which has shown high specificity against lactococcosis.
Lactococcosis is an emerging disease caused by bacteria, which affects several fish species and causes important economic losses in the aquaculture sector, among others.
The pathogen, having the greater economic impact in the farming trout, affects not just Spain but also other countries of the Mediterranean Basin.
The bacteria have been also isolated from human clinical episodes associated with severe infections and even septicemia.
The new antimicrobial compound can be used to combat the current problems of resistance and specificity facing the industry.

Bionaturis -BNT-MAB-, a leading global company in biological drugs development, and the Complutense University -Madrid- (UCM), have summited a joint patent application intended to protect a new antimicrobial peptide, Garvicin A. The invention provides a new compound and its corresponding formulations to be used as a high-specific antimicrobial product against Lactococcus garvieae, a pathogen bacteria affecting industrial sectors such as the dairy industry or trout fish farming, causing important economic losses annually.

 The novel peptide, not described so far, has shown promising specific in-vitro antibacterial activity. “The use of this unique bacteriocin could lead to a real alternative solution to prevent and treat lactococcosis, meaning a great saving to affected producers”, stated Alicia Gibello, main researcher at UCM.

Javier Gallastegui, the company’s managing director added: “we have chosen this product because its specificity, being able to use it to prevent and treat lactococcosis in living organisms without affecting the natural biota balance of the body. Besides, it’s an alternative over conventional antibiotics where the problem of resistance is an issue of major concerns of global health authorities”. Thus, the biotech company adds a new product to its portfolio of state-of-the-art […]

May 7th, 2013|last news, Press english|0 Comments

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR